We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Molecular and Cytogenetic Characterization of Myelodysplastic Syndromes in Cell-Free DNA

By LabMedica International staff writers
Posted on 04 Mar 2022
Print article
Image: The Qubit 3 Fluorometer is the next generation of the popular benchtop fluorometer that accurately measures DNA, RNA, and protein using the highly sensitive fluorescence-based Qubit quantitation assays (Photo courtesy of Thermo Fisher Scientific)
Image: The Qubit 3 Fluorometer is the next generation of the popular benchtop fluorometer that accurately measures DNA, RNA, and protein using the highly sensitive fluorescence-based Qubit quantitation assays (Photo courtesy of Thermo Fisher Scientific)

Molecular and cytogenetic studies are essential in patients with myelodysplastic syndromes (MDS) for diagnosis and prognosis. Cell-free DNA (cfDNA) analysis has been reported as a reliable non-invasive approach for detecting molecular abnormalities in MDS, however, there is limited information about cytogenetic alterations and monitoring in cfDNA.

Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders characterized by dysplasia and ineffective hematopoiesis that are driven by somatically acquired genomic alterations.

Molecular studies and conventional cytogenetics are essential in MDS to establish a correct diagnosis and to set up accurate risk stratification. Routinely, these analyses are performed in bone marrow (BM) samples, in particular cytogenetic analysis as it is difficult to obtain metaphases from peripheral blood (PB) samples.

Clinical Scientists at the Institut Hospital del Mar d'Investigacions Mèdiques (Barcelona, Spain) and their colleagues assessed the molecular and cytogenetic profile of a cohort of 70 patients with MDS by next-generation sequencing (NGS) using cfDNA and compared the results to paired bone marrow (BM) DNA.

BM aspirates were collected and BM DNA was extracted with MagAttract DNA Blood Mini M48 Kit (Qiagen, Hilden, Germany). Cell-free DNA (CfDNA) was isolated automatically using Qiagen’s QIAsymphony SP (QIAsymphony DSP Virus/Pathogen Kit) and quantified with Qubit 3.0 (Thermo Fisher Scientific, Eugene, OR, USA). Genomic characterization was performed in paired sample of BM DNA and cfDNA by next-generation sequencing (NGS) in all patients. Libraries were prepared using a custom panel including 48 myeloid-associated genes. Libraries were sequenced with a 3000× minimum read depth in MiSeq/NextSeq (Illumina, San Diego, CA, USA).

The scientists reported that the amount of total cfDNA obtained in MDS patients (median: 58.4 ng/L) was significantly higher than that obtained from healthy controls (median: 32.4 ng/mL). A positive correlation was observed between the amount of cfDNA and the serum lactate dehydrogenase (LDH) levels. Mutational profiling of BM DNA and cfDNA showed comparable results: mutations were detected in BM DNA and cfDNA, with a 92.1% concordance.

The most frequently 140 mutated genes were TET2 (45.7%), SF3B1 (37.1%), ASXL1 (21.4%), DNMT3A (20.0%), SRSF2 141 (15.7%), ZRSR2 (11.4%) and U2AF1 (11.4%). A strong correlation was observed between the variant allele frequencies (VAF) of BM and cfDNA. The team compared the VAF of the detected mutations in cfDNA and BM DNA grouped by gene and observed that VAFs of SF3B1 mutations were significantly higher in cfDNA than in BM DNA. Cytogenetic/FISH alterations were detected at the time of diagnosis in 20/70 (28.6%) MDS patients. NGS analysis detected abnormalities in 10/70 MDS patients, in both BM DNA and cfDNA.

The authors concluded that that cfDNA mirrors the molecular profile of BM in MDS. In their cohort, enriched with lower risk patients, cytogenetic alterations were detectable in most cases by NGS in both BM DNA and cfDNA. Although further studies with larger cohorts are required to confirm these results, especially for cytogenetic alterations, our data support that the analysis of cfDNA is a promising method to characterize and monitor the molecular abnormalities present in patients with MDS. The study was published on February 22, 2022 in the journal Blood Advances.

Related Links:
Institut Hospital del Mar d'Investigacions Mèdiques 
Qiagen 
Thermo Fisher Scientific 
Illumina 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.